Accelrys Posts 3-Percent Rise in Q3 Revenue; Eyes 'Right M&A Opportunities' | GenomeWeb

Accelrys this week reported that third-quarter revenues rose 5 percent as a loss in the prior-year quarter swung to a profit, and a senior official said the company continues to eye "the right M&A opportunities."

Interim CEO Todd Johnson told investors during the firm's earnings conference call this week that he is "pleased" with the company's "rock-solid financials," and said the firm expects to add to its headcount during the year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.